1stOncology™: Cancer Intelligence Service – Page 5172 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call

On March 7, 2023 MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported that the Company will release its financial results for the fourth quarter of 2022 after the market closes on Wednesday, March 15, 2023 (Press release, MacroGenics, MAR 7, 2023, View Source [SID1234628275]). MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Wednesday, March 15, 2023, at 4:30 pm ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Conference Call Information

To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company’s website at View Source A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.

MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference

On March 7, 2023 MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, reported that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a virtual presentation at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 2:00 pm (ET) (Press release, Mannkind, MAR 7, 2023, View Source [SID1234628274]).

Interested parties can access a link to the webcast from the News & Events section of the Company’s website at Events & Presentations. The webcast replay will remain available for 14 days following the live presentation.

Cyclacel Pharmaceuticals to Participate in March Investor Conferences

On March 7, 2023 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, reported that the Company plans to participate in a fireside chat and host one-on-one meetings at two investor conferences (Press release, Cyclacel, MAR 7, 2023, View Source [SID1234628273]).

Oppenheimer 33rd Annual Healthcare Conference:

Location: Virtual
Format: Fireside chat and one-on-one meetings
Date: March 13-15, 2023
Fireside chat: March 13, 10:00am ET
Presenter: Spiro Rombotis
Webcast: Link
35th Annual Roth Conference:

Location: Dana Point, CA
Format: Fireside chat and one-on-one meetings
Date: March 12-14, 2023
Fireside chat: March 13, 3:00pm PT
Presenter: Paul McBarron
Webcast: Link

About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel’s strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.

Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023

On March 7, 2023 Omeros Corporation (NASDAQ: OMER), reported that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022, on Monday, March 13, 2023, after the market closes (Press release, Omeros, MAR 7, 2023, View Source [SID1234628272]). Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.

Conference Call Details

To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you will have two options: (1) Dial in to the conference line provided at the registration site using the PIN provided to you, or (2) choose the "Call Me" option, which will instantly dial the phone number you provide. Should you lose your PIN or registration confirmation email, simply re-register to receive a new PIN.

The live or subsequently archived webcast of the event can be accessed at this link.

Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

On March 7, 2023 Indaptus Therapeutics, Inc. (Nasdaq: INDP, "Indaptus" or "the Company"), a biotechnology company focused on discovering and developing transformative therapeutics for patients, reported the dosing of the first subject in INDP-D101 (Press release, Indaptus Therapeutics, MAR 7, 2023, View Source;qmodStoryID=6511274850645070 [SID1234628271]). INDP-D101 is the Company’s first-in-human, open label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound Decoy20 in patients with advanced/metastatic solid tumors.

After Decoy20 dosing, the subject experienced expected and manageable adverse events believed to be related to the immune system activating components known to be in the product. A second subject in the first three-subject cohort is expected to be enrolled following final assessment of the safety and tolerability associated with dosing of the first subject, per the study protocol.

"Following dosing of our first subject in INDP-D101, we are optimistic regarding our expectations for this part of the trial," said Michael Newman, Ph.D., the Company’s founder and chief scientific officer. "Our hypothesis for the invention and development of Decoy20 was based on attenuation and killing of non-pathogenic bacteria to produce a product with a novel, less toxic and potentially more effective ratio of immune stimulating components. We are encouraged that the initial adverse event profile exhibited by our first subject appears to be consistent with this hypothesis."

The study’s objectives are to assess the safety and tolerability of Decoy20, to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as well as to assess Decoy20 pharmacokinetics (PK), pharmacodynamics and clinical activity.

The Phase 1 study was initiated with a single dose escalation, which is planned to be followed by an expansion with continuous weekly administration of Decoy20. The study is enrolling patients with advanced/metastatic solid tumors, who have exhausted approved treatment options. More information can be found at www.clinicaltrials.gov.

The primary endpoint of the study is incidence, relatedness and severity of adverse events and treatment-emergent adverse events and determination of the number of subjects per cohort with dose limiting toxicity-based adverse events. Secondary endpoints include the incidence of anti-drug antibodies and neutralizing antibodies pre- and post-treatment, change in Decoy20 PK parameters over time, objective response rate in subjects with measurable disease and duration of response. More information can be found at www.clinicaltrials.gov.